Areteia Therapeutics, a Chapel Hill, NC-based clinical stage biotechnology company, raised additional $75M in Series A funding.
The round, which brought the total amount to $425M, saw support from Viking Global Investors and Marshall Wace, who joined the original syndicate of investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.
The company intends to use the funds to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma.
Led by CEO and President Jorge Bartolome, Areteia Therapeutics is a clinical stage biotechnology company whose purpose is to develop and deliver novel Inflammation and Immunology therapies that put respiratory patients in control of their disease and back in control of their lives. Its lead drug candidate is dexpramipexole, and if approved, will be anoral eosinophil maturation inhibitor that targets eosinophilic inflammation by lowering blood and tissue eosinophils.
Areteia has initiated late-stage development of dexpramipexole in eosinophilic asthma, including three Phase III clinical trials in partnership with Population Health Partners’ development unit, Validae Health.
FinSMEs
14/02/2024